Management

Management & rehab

There is no pill that grows back a vestibular organ. Stop whatever is still causing harm, then rebuild function through rehabilitation — and, for the worst-affected, watch the vestibular implant.

The principle

Trainee

Management has three strands. Stop the cause (discontinue the aminoglycoside; treat autoimmune or infective causes). Rehabilitate with supervised gaze-stabilisation and substitution training, which improve gaze stability, balance and gait.2 And avoid vestibular suppressants, which blunt the central adaptation rehabilitation depends on.1

The management ladder

Find and stop the cause; make vestibular rehabilitation the mainstay; then layer in practical strategies, aids and — where appropriate — emerging therapy.

step 1

Find & stop the cause

  • Stop the ototoxinDiscontinue the offending aminoglycoside wherever possible — halting an ongoing insult is the single most important step.
  • Treat treatable causesImmunosuppression for autoimmune disease, treatment of infection, and a search for CANVAS/genetic and neoplastic (NF2) causes.
  • Confirm & documentEstablish the bilateral deficit with caloric, vHIT and/or rotational-chair testing before committing to lifelong management.
step 2

Vestibular rehabilitation — mainstay

  • Gaze stabilisation×1 and ×2 viewing exercises drive adaptation and reduce oscillopsia; supervised programmes work best.
  • Substitution & balanceTrain use of vision and proprioception, plus saccadic/pursuit strategies and balance work for gait stability.
  • Avoid suppressantsVestibular sedatives blunt central compensation and worsen outcome — they have no role in chronic bilateral loss.
step 3

Strategies, aids & future therapy

  • Practical strategiesGood lighting, walking aids, fall prevention, and caution with driving where head-movement vision is critical.
  • Vestibular implantAn emerging neuroprosthesis for severe, refractory bilateral loss — investigational but restores a measurable VOR.

Stop any ongoing cause first, then rehabilitation is the mainstay — there is no drug that restores lost vestibular function. Reserve the vestibular implant for severe, refractory bilateral loss.

The course over time

Management unfolds from the work-up, through early and ongoing rehabilitation, to long-term strategies. Step through it:

Find & stop the cause · at diagnosis

Stop the offending aminoglycoside, treat autoimmune or infective causes, and screen for CANVAS/genetic and neoplastic causes. Halting an ongoing insult is the single most important step.

The rehabilitation programme itself is covered in Vestibular rehabilitation therapy; the functional impact of the VOR loss is quantified by dynamic visual acuity.

Key points

  • Stop the cause first — discontinuing an offending aminoglycoside is the single most important step.
  • Vestibular rehabilitation (gaze stabilisation + substitution) is the mainstay; supervised programmes work best.
  • Avoid vestibular suppressants — they blunt central compensation and worsen outcome.
  • Outcome is better with residual function than complete areflexia; the vestibular implant is an emerging option for severe loss.